CureVac N.V. (LON:0A9E)
3.111
+0.011 (0.36%)
At close: Apr 17, 2025
CureVac Revenue
In the year 2024, CureVac had annual revenue of 535.18M EUR with 895.54% growth. CureVac had revenue of 254.19M in the quarter ending December 31, 2024, with 1,026.36% growth.
Revenue
535.18M EUR
Revenue Growth
+895.54%
P/S Ratio
1.21
Revenue / Employee
544.44K EUR
Employees
983
Market Cap
537.36M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
Shell | 227.10B |
HSBC Holdings | 48.93B |
Unilever | 50.25B |
Rio Tinto Group | 42.86B |
RELX PLC | 9.43B |
British American Tobacco p.l.c. | 25.87B |
London Stock Exchange Group | 8.86B |
CureVac News
- 13 days ago - CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - CureVac BV reports Q4 results - Seeking Alpha
- 13 days ago - CureVac N.V. 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 14 days ago - CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - Accesswire
- 14 days ago - Earnings Scheduled For April 10, 2025 - Benzinga
- 14 days ago - Insights Ahead: CureVac's Quarterly Earnings - Benzinga
- 16 days ago - CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - Accesswire
- 16 days ago - CureVac to initiate Phase 1 trial for its lung cancer therapy - Seeking Alpha